With the past preclinical evidence and ongoing clinical trials in breast cancer (history of studying DDR in breast cancer (Fig. 1), we have summarized the DDR inhibitor practice and strategies for drug resistance, with a special concentration on the combined therapies with chemotherapy, radiotherapy, immunotherapies, and other DDR inhibitors. Here, DDR1 is linked to breast carcinoma.